• Best CPA Networks
  • Best Cost-Per-Sale Affiliate Networks
  • Best Pay-Per-Call Networks
  • mThink Digital
  • Thought Leadership
    • White Papers
  • About
    • Content Marketing
    • Content Strategy
      • Web Content
      • Social Media Strategy
      • Webinars & Video
      • Thought Leadership
    • Performance Marketing
    • Portfolio
      • Revenue Performance
      • Accenture
      • Microsoft
      • Java Detour
      • Our Process
    • Contact Us

mThink

Blue Book Logo

BlueBook Logo

The Trusted Name in Performance Marketing

ROS Leaderboard

  • Home
  • Blue Book
    • About Blue Book
    • Blue Ribbon Panel
    • Interviews
    • Research Methodology
    • Back Issues
    • Advertising
      • Website Creative Specifications
      • Newsletter Creative Specifications
  • Best CPA Networks
  • Best Cost-Per-Sale Affiliate Networks
  • Best Pay-Per-Call Networks
  • Best European CPA Networks
  • Best CPA Networks for Affiliates
  • Best CPA Networks for Advertisers

CBD: The FDA and State Attorneys General

August 16, 2019 by Richard B. Newman

Former U.S. Food and Drug Administration Commissioner Scott Gottlieb recent stated that, “the CBD craze is getting out of hand…”  Federal law currently permits for the distribution of hemp-derived CBD products that contain 0.3% THC or less to be sold, with certain exceptions.

The FDA has indicated that it will be increasing regulations, as well as making recommendation to Congress.  In fact, earlier this year, the FDA issued warning letters to  companies marketing and selling CBD products, all of whom were allegedly making improper disease-related prevention claims.  Most recently, the FDA alleged that a marketer made unsubstantiated claims regarding the “diagnosis, cure, mitigation, treatment, or prevention of disease and/or intended to affect the structure or any function of the body.”

At present, Sens. Dianne Feinstein and Susan Collins reintroduced the “Personal Care Products Safety Act” (S. 726) which would require the FDA to evaluate a minimum of five ingredients found in personal care products per year to determine their safety and appropriate use.  The review process set forth in the bill would provide companies with clear guidance about whether ingredients should continue to be used and whether consumer warnings are needed.  

State Attorneys General Activity

Uncertainty remains about federal enforcement related to the hemp and cannabis industry, including how FTC lawyers may regulate advertising.  To date, federal enforcement has been rather passive.

In addition to FDA regulations and activity relating to FDA, it is anticipated that FTC lawyers and state attorneys general will soon be ramping-up enforcement of CBD products and related marketing.

At the state level, Governor Andrew Cuomo of New York recently signed into law a bill decriminalizing marijuana.  Hawaii has also done recently done so.

State AGs, have not and will actively police unsubstantiated representations, including alleged health benefits of hemp and cannabis products.  More than 30 state attorneys general recently submitted a letter to the FDA about associated risks when it comes to mislabeling help and cannabis products, as well as other dietary supplements.

It is almost certain that state AGs will pursue CBD companies that make false, misleading or deceptive representations, including via the issuance of aggressive civil investigative demands (CIDs).

Contact experienced FTC lawyers if you have questions about complying with applicable advertising regulations, or if you are the subject of an FTC CID investigation or enforcement action.

Richard B. Newman is a digital advertising and compliance lawyer at Hinch Newman LLP. 

Attorney Advertising. Informational purposes only. Not legal advice.

Related posts:

  1. FTC Attorneys Announce “Back-to-Basics” Advertising and Data Security Workshop The Federal Trade Commission has announced that, along with its...
  2. TCPA Robocall and State Privacy Legislation Update The Federal Communications Commission considers the definition of an automatic...
  3. FTC Warns Marketers to Take CIDs and Subpoenas Seriously The Federal Trade Commission obtains information through subpoenas and civil...
  4. FTC Signs Consumer Protection MOU With UK Regulator The Federal Trade Commission has signed a memorandum of understanding...

Filed Under: Blue Book, Revenue, Revenue Blog Tagged With: cannabis, CBD, FDA, Federal trade commission

Search

ROS Col 2 Top

ROS Col 2 Mid

ROS Col 2 Low

Subscribe to our newsletter!

* indicates required

ROS Col 2 – 4 Misc

ROS Col 2 – 5 Misc

ROS Col 2 – 6 Misc

Recent Posts

  • 2023: Challenges, Opportunities & Predictions
  • Top 4 Best Practices For Consumer Finance Campaigns
  • Four Moments That Changed Performance Marketing Forever
  • New additions, improvements, and added perks from your favorite CPA network
  • Your Top 5 Affiliate Marketing Questions Answered
  • 5 strategies to create better content
  • FCC Says Ringless Voicemails Require Prior Consent
  • Top 5 Free Methods to Increase Affiliate Traffic
  •  3 Top Lead Generation Best Practices To Scale Your Business
  • Automation, Conversions, Profitability, Oh My – Breaking Affiliate Campaign Roadblocks
  • 5 tips for a better brand image
  • How Mac of All Trades Found Multi-Channel Success
  • Winning In A Changing World: An Interview with Taras Kiseliuk, CEO of ClickDealer
  • Survey: What Consumers Want from Financial Services Providers
  • The influencer marketing era: what does the future of web marketing hold?

About mThink

mThink is a specialist digital marketing company based in San Francisco. We focus on media buying, Facebook marketing, direct response, social and mobile. In addition mThink produces the annual Blue Book Rankings of major performance marketing networks. Read More »

Baseboard

Copyright ©2023 · mThink. All rights reserved.
3053 Fillmore Street, Suite 325 | (415) 787-0250
Disclaimer | Privacy Policy